公开(公告)号：US11730800B2

公开(公告)日：2023-08-22

申请号：US17024618

申请日：2020-09-17

申请人： PFIZER INC.

发明人： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Judith Absalon ,  Jose Miguel Aste-Amezaga ,  Johannes Frederik Beeslaar ,  David Cooper ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Thomas Richard Jones ,  Isis Kanevsky ,  Lakshmi Khandke ,  Paul Liberator ,  John Lance Perez ,  Lynn Marie Phelan ,  Gary Warren Zlotnick

IPC分类号： A61K39/095 ,  A61K47/64 ,  C07K14/22 ,  C07K16/12 ,  A61K39/00 ,  A61K47/18 ,  A61K47/10 ,  A61K47/26 ,  A61K31/7028 ,  A61P31/00 ,  A61K39/12

CPC分类号： A61K39/095 ,  A61K31/7028 ,  A61K39/12 ,  A61K47/10 ,  A61K47/183 ,  A61K47/26 ,  A61K47/646 ,  A61K47/6415 ,  A61P31/00 ,  C07K14/22 ,  C07K16/1217 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/55505 ,  A61K2039/6037 ,  A61K2039/70 ,  C12N2770/32434

摘要： In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

公开(公告)号：US11680087B2

公开(公告)日：2023-06-20

申请号：US17126712

申请日：2020-12-18

申请人： Pfizer Inc.

发明人： Annaliesa Sybil Anderson ,  Rasappa Gounder Arumugham ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Kathrin Ute Jansen ,  Thomas Richard Jones ,  Lakshmi Khandke ,  Bounthon Loun ,  John Lance Perez ,  Gary Warren Zlotnick

IPC分类号： A61K39/05 ,  C07K14/22 ,  A61K39/00 ,  A61K39/13 ,  A61K39/295 ,  A61K39/095 ,  A61K39/12 ,  A61K39/39 ,  C12N7/00

CPC分类号： C07K14/22 ,  A61K39/0016 ,  A61K39/095 ,  A61K39/12 ,  A61K39/13 ,  A61K39/295 ,  A61K39/39 ,  C12N7/00 ,  A61K2039/5252 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/70 ,  C12N2710/20034 ,  C12N2770/32634 ,  Y02A50/30

摘要： In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

公开(公告)号：US10813989B2

公开(公告)日：2020-10-27

申请号：US16704701

申请日：2019-12-05

申请人： PFIZER INC.

发明人： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Judith Absalon ,  Jose Miguel Aste-Amezaga ,  Johannes Frederik Beeslaar ,  David Cooper ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Thomas Richard Jones ,  Isis Kanevsky ,  Lakshmi Khandke ,  Paul Liberator ,  John Lance Perez ,  Lynn Marie Phelan ,  Gary Warren Zlotnick

IPC分类号： A61K39/095 ,  A61K31/7028 ,  A61K47/10 ,  A61K47/18 ,  C07K14/22 ,  C07K16/12 ,  A61K47/26 ,  A61K47/64 ,  A61P31/00 ,  A61K39/12 ,  A61K39/00

摘要： In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

公开(公告)号：US10183070B2

公开(公告)日：2019-01-22

申请号：US15883334

申请日：2018-01-30

申请人： PFIZER INC.

发明人： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Judith Absalon ,  Jose Miguel Aste-Amezaga ,  Johannes Frederik Beeslaar ,  David Cooper ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Thomas Richard Jones ,  Isis Kanevsky ,  Lakshmi Khandke ,  Paul Liberator ,  John Lance Perez ,  Lynn Marie Phelan ,  Gary Warren Zlotnick

IPC分类号： A61K39/095 ,  A61K31/7028 ,  A61K47/10 ,  A61K47/18 ,  C07K14/22 ,  C07K16/12 ,  A61K47/26 ,  A61K47/64 ,  A61P31/00

摘要： In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

公开(公告)号：US20160030543A1

公开(公告)日：2016-02-04

申请号：US14604620

申请日：2015-01-23

申请人： PFIZER INC.

发明人： Gary Warren Zlotnick ,  Susan Kay Hoiseth ,  Kathrin Ute Jansen ,  Justin Keith Moran ,  Mark E. Ruppen ,  Annaliesa Sybil Anderson ,  John Erwin Farley ,  Liesel A. Bernfield

IPC分类号： A61K39/095 ,  C07K14/22

CPC分类号： A61K39/095 ,  A61K2039/55577 ,  A61K2039/6018 ,  C07K14/22 ,  C07K16/1217

摘要： In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.

公开(公告)号：US10899802B2

公开(公告)日：2021-01-26

申请号：US15728610

申请日：2017-10-10

申请人： Pfizer Inc.

发明人： Annaliesa Sybil Anderson ,  Rasappa Gounder Arumugham ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Kathrin Ute Jansen ,  Thomas Richard Jones ,  Lakshmi Khandke ,  Bounthon Loun ,  John Lance Perez ,  Gary Warren Zlotnick

IPC分类号： C07K14/22 ,  A61K39/00 ,  C12N7/00 ,  A61K39/13 ,  A61K39/295 ,  A61K39/095 ,  A61K39/12 ,  A61K39/39

摘要： In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

公开(公告)号：US20180022783A1

公开(公告)日：2018-01-25

申请号：US15728610

申请日：2017-10-10

申请人： Pfizer Inc.

发明人： Annaliesa Sybil Anderson ,  Rasappa Gounder Arumugham ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Kathrin Ute Jansen ,  Thomas Richard Jones ,  Lakshmi Khandke ,  Bounthon Loun ,  John Lance Perez ,  Gary Warren Zlotnick

IPC分类号： C07K14/22 ,  A61K39/39 ,  A61K39/295 ,  A61K39/00 ,  A61K39/12 ,  A61K39/095 ,  C12N7/00 ,  A61K39/13

摘要： In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

公开(公告)号：US20210101943A1

公开(公告)日：2021-04-08

申请号：US17126712

申请日：2020-12-18

申请人： Pfizer Inc.

发明人： Annaliesa Sybil Anderson ,  Rasappa Gounder Arumugham ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Kathrin Ute Jansen ,  Thomas Richard Jones ,  Lakshmi Khandke ,  Bounthon Loun ,  John Lance Perez ,  Gary Warren Zlotnick

IPC分类号： C07K14/22 ,  A61K39/13 ,  A61K39/295 ,  A61K39/00 ,  A61K39/095 ,  A61K39/12 ,  A61K39/39 ,  C12N7/00

摘要： In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

公开(公告)号：US10543267B2

公开(公告)日：2020-01-28

申请号：US16196150

申请日：2018-11-20

申请人： PFIZER INC.

发明人： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Judith Absalon ,  Jose Miguel Aste-Amezaga ,  Johannes Frederik Beeslaar ,  David Cooper ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Thomas Richard Jones ,  Isis Kanevsky ,  Lakshmi Khandke ,  Paul Liberator ,  John Lance Perez ,  Lynn Marie Phelan ,  Gary Warren Zlotnick

IPC分类号： A61K39/095 ,  A61K31/7028 ,  A61K47/10 ,  A61K47/18 ,  C07K14/22 ,  C07K16/12 ,  A61K47/26 ,  A61K47/64 ,  A61P31/00

摘要： In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

公开(公告)号：US20150071959A1

公开(公告)日：2015-03-12

申请号：US14470922

申请日：2014-08-27

申请人： Pfizer Inc.

发明人： Annaliesa Sybil Anderson ,  Rasappa Gounder Arumugham ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Harris ,  Kathrin Ute Jansen ,  Thomas Richard Jones ,  Lakshmi Khandke ,  Bounthon Loun ,  John Lance Perez ,  Gary Warren Zlotnick

IPC分类号： C07K14/22 ,  C12N7/00 ,  A61K39/12 ,  A61K39/00 ,  A61K39/095 ,  A61K39/39

CPC分类号： C07K14/22 ,  A61K39/0016 ,  A61K39/095 ,  A61K39/12 ,  A61K39/13 ,  A61K39/295 ,  A61K39/39 ,  A61K2039/5252 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/20034 ,  C12N2770/32634 ,  Y02A50/466

摘要： In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

摘要翻译： 一方面，本发明涉及包含具有SEQ ID NO：1所示序列的第一多肽的组合物和具有SEQ ID NO：2所示序列的第二多肽。在一个实施方案中，组合物包含约120 μg/ ml的包含SEQ ID NO：1所示的氨基酸序列的第一多肽，120μg/ ml的包含SEQ ID NO：2所示的氨基酸序列的第二多肽，约2.8摩尔比的聚山梨醇酯-80 至第一多肽，约2.8摩尔比的聚山梨酯-80至第二多肽，约0.5mg / ml的铝，约10mM的组氨酸和约150mM的氯化钠。 在一个实施方案中，组合物的总剂量为约0.5ml。 在一个实施方案中，组合物的两剂量诱导针对人中不同异源亚家族A和亚科B菌株的杀菌效价。